APA (7th ed.) Citation

L, M., JS, N., J, T., F, Z., & JP, F. (2025). MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF: Differences in Diseases, Drugs, or Both? JACC. Heart failure, 13(8), 102514. https://doi.org/10.1016/j.jchf.2025.102514

Chicago Style (17th ed.) Citation

L, Mendonça, Neves JS, Testani J, Zannad F, and Ferreira JP. "MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF: Differences in Diseases, Drugs, or Both?" JACC. Heart Failure 13, no. 8 (2025): 102514. https://doi.org/10.1016/j.jchf.2025.102514.

MLA (9th ed.) Citation

L, Mendonça, et al. "MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF: Differences in Diseases, Drugs, or Both?" JACC. Heart Failure, vol. 13, no. 8, 2025, p. 102514, https://doi.org/10.1016/j.jchf.2025.102514.